Related Experiment Video
Updated: Jun 7, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with
Mara L Becker1, J Steven Leeder
1Division of Clinical Pharmacology and Toxicology, Children's Mercy Hospitals and Clinics, University of Missouri Kansas City, 2401 Gillham Road, Kansas City, MO 64108, USA.
Abstract:
Although methotrexate is widely used in clinical practice there remains significant lack of understanding of its mechanisms of action and the factors that contribute to the variability in toxicity and response seen clinically. In addition to differences in drug administration, factors that affect pharmacokinetics and pharmacodynamics such as genetic variation may explain individual differences in drug biotransformation. However, the pediatric population has an additional factor to consider, namely the ontogeny of gene expression which may result in variation throughout growth and development. We review the current understanding of methotrexate biotransformation and the concept of ontogeny, with further discussion of how to implement a developmental pharmacogenomics approach in future studies.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacogenomics: Identification of New Drug Targets
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacokinetics in Pediatric Patients: Drug Distribution